Blinded, multicenter comparison of methods to detect a drug-resistant mutant of human immunodeficiency virus type 1 at low frequency

被引：97

作者：

Halvas, Elias K.

Aldrovandi, Grace M.

Balfe, Peter

Beck, Ingrid A.

Boltz, Valerie F.

Coffin, John M.

Frenkel, Lisa M.

Hazelwood, J. Darren

Johnson, Victoria A.

Kearney, Mary

Kovacs, Andrea

Kuritzkes, Daniel R.

Metzner, Karin J.

Nissley, Dwight V.

Nowicki, Marek

Palmer, Sarah

Ziermann, Rainer

Zhao, Richard Y.

Jennings, Cheryl L.

Bremer, James

Brambilla, Don

Mellors, John W.

机构：

[1] Univ Pittsburgh, Dept Med, Div Infect Dis, Pittsburgh, PA 15261 USA

[2] Childrens Hosp Los Angeles, Keck Sch Med, Los Angeles, CA 90027 USA

[3] Columbia Univ, New York, NY USA

[4] Univ Washington, Seattle, WA 98195 USA

[5] NCI, HIV Drug Resistance Program, Frederick, MD 21701 USA

[6] Birmingham VA Med Ctr, Birmingham, AL USA

[7] Univ Alabama, Birmingham, AL USA

[8] Univ So Calif, Los Angeles, CA USA

[9] Brigham & Womens Hosp, Sect Retroviral Therapeut, Boston, MA 02115 USA

[10] Harvard Univ, Sch Med, Div AIDS, Boston, MA USA

[11] Univ Erlangen Nurnberg, Erlangen, Germany

[12] NCI, Basic Res Program, SAIC Frederick, Frederick, MD 21701 USA

[13] Bayer Healthcare Diagnost, Berkeley, CA USA

[14] Univ Maryland, Sch Med, Baltimore, MD 21201 USA

[15] Rush Med Coll, Chicago, IL 60612 USA

[16] New England Res Inst, Watertown, MA 02172 USA

来源：

JOURNAL OF CLINICAL MICROBIOLOGY | 2006年 / 44卷 / 07期

关键词：

D O I：

10.1128/JCM.00449-06

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

We determined the abilities of 10 technologies to detect and quantify a common drug-resistant mutant of human immunodeficiency virus type 1 (lysine to asparagine at codon 103 of the reverse transcriptase) using a blinded test panel containing mutant-wild-type mixtures ranging from 0.01% to 100% mutant. Two technologies, allele-specific reverse transcriptase PCR and a Ty1HRT yeast system, could quantify the mutant down to 0.1 to 0.4%. These technologies should help define the impact of low-frequency drug-resistant mutants on response to antiretroviral therapy.

引用

收藏

页码：2612 / 2614

页数：3

相关论文

共 20 条

[1] HIV POPULATION-DYNAMICS IN-VIVO - IMPLICATIONS FOR GENETIC-VARIATION, PATHOGENESIS, AND THERAPY [J].

COFFIN, JM .

SCIENCE, 1995, 267 (5197) :483-489

[2] Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. [J].

Deeks, SG ;

Wrin, T ;

Liegler, T ;

Hoh, R ;

Hayden, M ;

Barbour, JD ;

Hellmann, NS ;

Petropoulos, CJ ;

McCune, JM ;

Hellerstein, MK ;

Grant, RM .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (07) :472-480

[3] Re-occurrence of HIV-1 drug mutations after treatment re-initiation following interruption in patients with multiple treatment failure [J].

Delaugerre, C ;

Valantin, MA ;

Mouroux, M ;

Bonmarchand, M ;

Carcelain, G ;

Duvivier, C ;

Tubiana, R ;

Simon, A ;

Bricaire, F ;

Agut, H ;

Autran, B ;

Katlama, C ;

Calvez, V .

AIDS, 2001, 15 (16) :2189-2191

[4] Oligonucleotide ligation assay for detecting mutations in the human immunodeficiency virus type 1 pol gene that are associated with resistance to zidovudine, didanosine, and lamivudine [J].

Edelstein, RE ;

Nickerson, DA ;

Tobe, VO ;

Manns-Arcuino, LA ;

Frenkel, LM .

JOURNAL OF CLINICAL MICROBIOLOGY, 1998, 36 (02) :569-572

[5]

Fontaine E, 2001, J ACQ IMMUN DEF SYND, V28, P254, DOI 10.1097/00042560-200111010-00008

[6] Changes in human immunodeficiency virus type 1 populations after treatment interruption in patients failing antiretroviral therapy [J].

Hance, AJ ;

Lemiale, V ;

Izopet, J ;

Lecossier, D ;

Joly, V ;

Massip, P ;

Mammano, F ;

Descamps, D ;

Brun-Vézinet, F ;

Clavel, F .

JOURNAL OF VIROLOGY, 2001, 75 (14) :6410-6417

[7] Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1:: 2003 recommendations of an international AIDS Society-USA panel [J].

Hirsch, MS ;

Brun-Vézinet, F ;

Clotet, B ;

Conway, B ;

Kuritzkes, DR ;

D'Aquila, RT ;

Demeter, LM ;

Hammer, SM ;

Johnson, VA ;

Loveday, C ;

Mellors, JW ;

Jacobsen, DM ;

Richman, DD .

CLINICAL INFECTIOUS DISEASES, 2003, 37 (01) :113-128

[8] Evolution of human immunodeficiency virus type 1 populations after resumption of therapy following interruption and shift in resistance genotype [J].

Izopet, J ;

Souyris, C ;

Hance, A ;

Sandres-Sauné, K ;

Alvarez, M ;

Pasquier, C ;

Clavel, F ;

Puel, J ;

Massip, P .

JOURNAL OF INFECTIOUS DISEASES, 2002, 185 (10) :1506-1510

[9] Replication of phenotypically mixed human immunodeficiency virus type 1 virions containing catalytically active and catalytically inactive reverse transcriptase [J].

Julias, JG ;

Ferris, AL ;

Boyer, PL ;

Hughes, SH .

JOURNAL OF VIROLOGY, 2001, 75 (14) :6537-6546

[10] 3′-minor groove binder-DNA probes increase sequence specificity at PCR extension temperatures [J].

Kutyavin, IV ;

Afonina, IA ;

Mills, A ;

Gorn, VV ;

Lukhtanov, EA ;

Belousov, ES ;

Singer, MJ ;

Walburger, DK ;

Lokhov, SG ;

Gall, AA ;

Dempcy, R ;

Reed, MW ;

Meyer, RB ;

Hedgpeth, J .

NUCLEIC ACIDS RESEARCH, 2000, 28 (02) :655-661